NICE does not recommend trabectedin taken with PLDH (which is short for pegylated liposomal doxorubicin hydrochloride) for women with relapsed platinum-sensitive ovarian cancer.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. The evidence provided did not show that trabectedin provides more benefit than the standard treatments currently used by people with relapsed platinum-sensitive ovarian cancer in the NHS, and it costs more, so NICE did not recommend it.

Get involved